Literature DB >> 23247101

Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Min-Chul Kim1, Jae-Min Song, Eunju O, Young-Man Kwon, Youn-Jeong Lee, Richard W Compans, Sang-Moo Kang.   

Abstract

The extracellular domain of M2 (M2e), a small ion channel membrane protein, is well conserved among different human influenza A virus strains. To improve the protective efficacy of M2e vaccines, we genetically engineered a tandem repeat of M2e epitope sequences (M2e5x) of human, swine, and avian origin influenza A viruses, which was expressed in a membrane-anchored form and incorporated in virus-like particles (VLPs). The M2e5x protein with the transmembrane domain of hemagglutinin (HA) was effectively incorporated into VLPs at a several 100-fold higher level than that on influenza virions. Intramuscular immunization with M2e5x VLP vaccines was highly effective in inducing M2e-specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes in the absence of adjuvant. Importantly, immune sera were found to be sufficient for conferring protection in naive mice, which was long-lived and cross-protective. Thus, molecular designing and presenting M2e immunogens on VLPs provide a promising platform for developing universal influenza vaccines without using adjuvants.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247101      PMCID: PMC3594028          DOI: 10.1038/mt.2012.246

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  47 in total

1.  Predicting the evolution of human influenza A.

Authors:  R M Bush; C A Bender; K Subbarao; N J Cox; W M Fitch
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

2.  The decision to get vaccinated against influenza.

Authors:  Pedram Sendi; Rebecca Locher; Bruno Bucheli; Manuel Battegay
Journal:  Am J Med       Date:  2004-06-15       Impact factor: 4.965

3.  Preparing for the next pandemic.

Authors:  Michael T Osterholm
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

4.  Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.

Authors:  Krystyna Mozdzanowska; Jingqi Feng; Mark Eid; Darya Zharikova; Walter Gerhard
Journal:  Virology       Date:  2006-06-14       Impact factor: 3.616

5.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

6.  Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles.

Authors:  Jae-Min Song; Yeu-Chun Kim; Peter G Barlow; M Jaber Hossain; Kyoung-Mi Park; Ruben O Donis; Mark R Prausnitz; Richard W Compans; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2010-09-21       Impact factor: 5.970

7.  Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier.

Authors:  Roxana M Ionescu; Craig T Przysiecki; Xiaoping Liang; Victor M Garsky; Jiang Fan; Bei Wang; Robert Troutman; Yvette Rippeon; Elizabeth Flanagan; John Shiver; Li Shi
Journal:  J Pharm Sci       Date:  2006-01       Impact factor: 3.534

8.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

9.  The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.

Authors:  Fan Wu; Xiao-Yi Yuan; Jing Li; Ying-Hua Chen
Journal:  Vaccine       Date:  2009-05-14       Impact factor: 3.641

10.  Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.

Authors:  Jiang Fan; Xiaoping Liang; Melanie S Horton; Helen C Perry; Michael P Citron; Gwen J Heidecker; Tong-Ming Fu; Joseph Joyce; Craig T Przysiecki; Paul M Keller; Victor M Garsky; Roxana Ionescu; Yvette Rippeon; Li Shi; Michael A Chastain; Jon H Condra; Mary-Ellen Davies; Jason Liao; Emilio A Emini; John W Shiver
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

View more
  83 in total

Review 1.  Progress in developing virus-like particle influenza vaccines.

Authors:  Fu-Shi Quan; Young-Tae Lee; Ki-Hye Kim; Min-Chul Kim; Sang-Moo Kang
Journal:  Expert Rev Vaccines       Date:  2016-05-05       Impact factor: 5.217

2.  Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection.

Authors:  Min-Chul Kim; Jeong Woo Lee; Hyo-Jick Choi; Yu-Na Lee; Hye Suk Hwang; Jongsang Lee; Cheol Kim; Jong Seok Lee; Carlo Montemagno; Mark R Prausnitz; Sang-Moo Kang
Journal:  J Control Release       Date:  2015-05-21       Impact factor: 9.776

3.  M2e-immobilized gold nanoparticles as influenza A vaccine: Role of soluble M2e and longevity of protection.

Authors:  Wenqian Tao; Harvinder S Gill
Journal:  Vaccine       Date:  2015-04-02       Impact factor: 3.641

4.  Engineered influenza virions reveal the contributions of non-hemagglutinin structural proteins to vaccine mediated protection.

Authors:  Zhaochen Luo; Alanson W Girton; Brook E Heaton; Nicholas S Heaton
Journal:  J Virol       Date:  2021-03-03       Impact factor: 5.103

5.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

6.  Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.

Authors:  Junwei Li; Maria T Arévalo; Yanping Chen; Olivia Posadas; Jacob A Smith; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

7.  Virus-like particles presenting flagellin exhibit unique adjuvant effects on eliciting T helper type 1 humoral and cellular immune responses to poor immunogenic influenza virus M2e protein vaccine.

Authors:  Ki-Hye Kim; Young-Man Kwon; Young-Tae Lee; Hye Suk Hwang; Min-Chul Kim; Eun-Ju Ko; Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang
Journal:  Virology       Date:  2018-09-07       Impact factor: 3.616

8.  Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection.

Authors:  Min-Chul Kim; Yu-Na Lee; Eun-Ju Ko; Jong Seok Lee; Young-Man Kwon; Hye Suk Hwang; Jae-Min Song; Byung-Min Song; Youn-Jeong Lee; Jun-Gu Choi; Hyun-Mi Kang; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2014-03-04       Impact factor: 11.454

9.  Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Hye Suk Hwang; Jong Seok Lee; Ki-Hye Kim; Sang-Moo Kang
Journal:  Immunology       Date:  2014-10       Impact factor: 7.397

10.  Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Authors:  Young-Man Kwon; Youri Lee; Ki Hye Kim; Yu Jin Jung; Zhuo Li; Subbiah Jeeva; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-09-18       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.